138112-76-2 | N-[2-(7-methoxynaphthalen-1-yl)ethyl]acetamide

Packsize	Purity	Availability	Price	Discounted Price
5mg	95%	in stock	$8.00	$5.00
10mg	95%	in stock	$10.00	$7.00
50mg	95%	in stock	$20.00	$14.00
1g	95%	in stock	$26.00	$18.00
5g	95%	in stock	$110.00	$77.00
10g	95%	in stock	$208.00	$146.00
25g	95%	in stock	$423.00	$296.00
100g	95%	in stock	$1,022.00	$716.00

Description

• Catalog Number: AI33426
• Chemical Name: N-[2-(7-methoxynaphthalen-1-yl)ethyl]acetamide
• CAS Number: 138112-76-2
• Molecular Formula: C15H17NO2
• Molecular Weight: 243.30098000000007
• MDL Number: MFCD00916659
• SMILES: COc1ccc2c(c1)c(CCNC(=O)C)ccc2

Computed Properties

• Complexity: 280
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 18
• Hydrogen Bond Acceptor Count: 2
• Hydrogen Bond Donor Count: 1
• Rotatable Bond Count: 4
• XLogP3: 2.7

Literature

• Agomelatine: mechanism of action and pharmacological profile in relation to antidepressant properties.

  British journal of pharmacology 20140801

• Synthesis of new N-(arylcyclopropyl)acetamides and N-(arylvinyl)acetamides as conformationally-restricted ligands for melatonin receptors.

  Bioorganic & medicinal chemistry letters 20130115

• Cardiovascular effects of melatonin receptor agonists.

  Expert opinion on investigational drugs 20121101

• Circadian rhythms in obsessive-compulsive disorder.

  Journal of neural transmission (Vienna, Austria : 1996) 20121001

• Role of melatonin in mood disorders and the antidepressant effects of agomelatine.

  Expert opinion on investigational drugs 20121001

• Agomelatine may improve REM sleep behavior disorder symptoms.

  Journal of clinical psychopharmacology 20121001

• Melatonin and synthetic melatonergic agonists: actions and metabolism in the central nervous system.

  Central nervous system agents in medicinal chemistry 20120901

• Endpoints of drug discovery for menopausal vasomotor symptoms: interpretation of data from a proxy of disease.

  Menopause (New York, N.Y.) 20120801

• Agomelatine treatment with adolescents with ADHD.

  Journal of attention disorders 20120801

• Agomelatine versus venlafaxine XR in the treatment of anhedonia in major depressive disorder: a pilot study.

  Journal of clinical psychopharmacology 20120801

• (1-{[2-(6-Methoxynaphthalen-1-yl)ethyl]amino}ethylidene)oxidanium bromide monohydrate.

  Acta crystallographica. Section C, Crystal structure communications 20120801

• Agomelatine for the treatment of posttraumatic stress disorder: a case report.

  Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists 20120801

• The antidepressant agomelatine inhibits stress-mediated changes in amino acid efflux in the rat hippocampus and amygdala.

  Brain research 20120723

• Anticonvulsant effects of agomelatine in mice.

  Epilepsy & behavior : E&B 20120701

• Agomelatine prevents relapse in generalized anxiety disorder: a 6-month randomized, double-blind, placebo-controlled discontinuation study.

  The Journal of clinical psychiatry 20120701

• Agomelatine (S20098) modulates the expression of cytoskeletal microtubular proteins, synaptic markers and BDNF in the rat hippocampus, amygdala and PFC.

  Psychopharmacology 20120601

• Agomelatine-induced akathisia with concomitant duloxetine medication: a case report.

  Pharmacopsychiatry 20120601

• Fluoxetine increases the expression of NCAM140 and pCREB in rat C6 glioma cells.

  Psychiatry investigation 20120601

• Melatonin and its analogs in insomnia and depression.

  Journal of pineal research 20120501

• The effect of agomelatine on 5HT(2C) receptors in humans: a clinically relevant mechanism?

  Psychopharmacology 20120501

• Treating ADHD with agomelatine.

  Journal of attention disorders 20120501

• The long-term abnormalities in circadian expression of Period 1 and Period 2 genes in response to stress is normalized by agomelatine administered immediately after exposure.

  European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 20120301

• Design, synthesis and pharmacological evaluation of new series of naphthalenic analogues as melatoninergic (MT1/MT2) and serotoninergic 5-HT2C dual ligands (I).

  European journal of medicinal chemistry 20120301

• Emerging drugs for major depressive disorder.

  Expert opinion on emerging drugs 20120301

• Melatonergic drugs for therapeutic use in insomnia and sleep disturbances of mood disorders.

  CNS & neurological disorders drug targets 20120301

• Agomelatine and the brave old world of narrative-based medicine.

  Evidence-based mental health 20120201

• Agomelatine suppresses locomotor hyperactivity in olfactory bulbectomised rats: a comparison to melatonin and to the 5-HT(2c) antagonist, S32006.

  European journal of pharmacology 20120105

• Agomelatine improves sleep in a patient with fatal familial insomnia.

  Pharmacopsychiatry 20120101

• Clinically significant drug interactions with newer antidepressants.

  CNS drugs 20120101

• Validated LC-MS/MS method for quantification of agomelatine in human plasma and its application in a pharmacokinetic study.

  Journal of mass spectrometry : JMS 20120101

• Emerging targets for the pharmacological treatment of depression: focus on melatonergic system.

  Current medicinal chemistry 20120101

• Neuroimmune endocrine effects of antidepressants.

  Neuropsychiatric disease and treatment 20120101

• Agomelatine: an antidepressant without deterioration of sexual response.

  Journal of sex & marital therapy 20120101

• Translatability scoring in drug development: eight case studies.

  Journal of translational medicine 20120101

• Neurobiology, pathophysiology, and treatment of melatonin deficiency and dysfunction.

  TheScientificWorldJournal 20120101

• Treatment-resistant Schizophrenia: Evidence-based Strategies.

  Mens sana monographs 20120101

• Treatment-resistant depression: therapeutic trends, challenges, and future directions.

  Patient preference and adherence 20120101

• Recent progress in the development of agonists and antagonists for melatonin receptors.

  Current medicinal chemistry 20120101

• [Emotional disorders in the pathogenesis of cervical headache].

  Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 20120101

• Inflammation-related disorders in the tryptophan catabolite pathway in depression and somatization.

  Advances in protein chemistry and structural biology 20120101

• Synergistic mechanisms involved in the antidepressant effects of agomelatine.

  European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 20120101

• Circadian dimension and severity of depression.

  European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 20120101

• Onset, time course and trajectories of improvement with antidepressants.

  European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 20120101

• Anhedonia and major depression: the role of agomelatine.

  European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 20120101

• Relief of intractable posthypoxic myoclonus after administration of agomelatine.

  Clinical neuropharmacology 20120101

• Agomelatine augmentation of escitalopram therapy in treatment-resistant obsessive-compulsive disorder: a case report.

  Case reports in psychiatry 20120101

• Toward the definition of stereochemical requirements for MT2-selective antagonists and partial agonists by studying 4-phenyl-2-propionamidotetralin derivatives.

  Journal of medicinal chemistry 20111222

• Melatonin receptor agonists: new options for insomnia and depression treatment.

  CNS neuroscience & therapeutics 20111201

• Chronic agomelatine and fluoxetine induce antidepressant-like effects in H/Rouen mice, a genetic mouse model of depression.

  Pharmacology, biochemistry, and behavior 20111201

• Mode of action of agomelatine: synergy between melatonergic and 5-HT2C receptors.

  The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry 20111201

• Could the underestimation of bipolarity obstruct the search for novel antidepressant drugs?

  Expert opinion on pharmacotherapy 20111201

• The effects of agomelatine on sexual function in depressed patients and healthy volunteers.

  Human psychopharmacology 20111201

• Efficacy of antidepressants for late-life depression: a meta-analysis and meta-regression of placebo-controlled randomized trials.

  The Journal of clinical psychiatry 20111201

• Pharmacotherapy of anxiety disorders: a critical review.

  Dialogues in clinical neuroscience 20111201

• The influence of melatonin and agomelatine on urodynamic parameters in experimental overactive bladder model--preliminary results.

  Postepy higieny i medycyny doswiadczalnej (Online) 20111123

• The depression market.

  Nature reviews. Drug discovery 20111031

• Chronic agomelatine treatment corrects behavioral, cellular, and biochemical abnormalities induced by prenatal stress in rats.

  Psychopharmacology 20111001

• Chronic stress and antidepressant agomelatine induce region-specific changes in synapsin I expression in the rat brain.

  Journal of neuroscience research 20111001

• N-Acetyl-5-arylalkoxytryptamine analogs: probing the melatonin receptors for MT(1) -selectivity.

  Archiv der Pharmazie 20111001

• Agomelatine for the treatment of major depressive disorder.

  Expert opinion on pharmacotherapy 20111001

• Agomelatine: protecting the CNS from the effects of stress.

  CNS neuroscience & therapeutics 20111001

• [Depressive disorder, treatment and sexual dysfunction--part II].

  Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego 20111001

• Agomelatine facilitates positive versus negative affective processing in healthy volunteer models.

  Journal of psychopharmacology (Oxford, England) 20110901

• Comparison of agomelatine and escitalopram on nighttime sleep and daytime condition and efficacy in major depressive disorder patients.

  International clinical psychopharmacology 20110901

• A benefit-risk assessment of agomelatine in the treatment of major depression.

  Drug safety 20110901

• Agomelatine: a narrative review.

  European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 20110901

• Publication bias and outcome reporting bias: agomelatine as a case example.

  Journal of psychosocial nursing and mental health services 20110901

• A consensus statement for safety monitoring guidelines of treatments for major depressive disorder.

  The Australian and New Zealand journal of psychiatry 20110901

• Chronotherapeutics and psychiatry: setting the clock to relieve the symptoms.

  The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry 20110901

• Therapeutic potential of melatonin and its analogs in Parkinson's disease: focus on sleep and neuroprotection.

  Therapeutic advances in neurological disorders 20110901

• Novel melatonin-based therapies: potential advances in the treatment of major depression.

  Lancet (London, England) 20110813

• Strategies to achieve clinical effectiveness: refining existing therapies and pursuing emerging targets.

  Journal of affective disorders 20110801

• The melatonergic agonist and clinically active antidepressant, agomelatine, is a neutral antagonist at 5-HT(2C) receptors.

  The international journal of neuropsychopharmacology 20110701

• 7-Meth-oxy-3,4-dihydro-naphthalen-1(2H)-one.

  Acta crystallographica. Section E, Structure reports online 20110701

• [The effects of antidepressants on sleep in depressed patients with particular reference to trazodone in comparison to agomelatine, amitriptyline, doxepin, mianserine and mirtazapine].

  Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego 20110701

• Memory facilitating effects of agomelatine in the novel object recognition memory paradigm in the rat.

  Pharmacology, biochemistry, and behavior 20110601

• Melatonin agonists in primary insomnia and depression-associated insomnia: are they superior to sedative-hypnotics?

  Progress in neuro-psychopharmacology & biological psychiatry 20110601

• Neurochemical and neuropharmacological aspects of circadian disruptions: an introduction to asynchronization.

  Current neuropharmacology 20110601

• Modulation of neuroplastic molecules in selected brain regions after chronic administration of the novel antidepressant agomelatine.

  Psychopharmacology 20110501

• Focus on agomelatine.

  Current medical research and opinion 20110401

• Efficacy of antidepressants for dysthymia: a meta-analysis of placebo-controlled randomized trials.

  The Journal of clinical psychiatry 20110401

• Agomelatine reverses the decrease in hippocampal cell survival induced by chronic mild stress.

  Behavioural brain research 20110317

• Cartesian theories on the passions, the pineal gland and the pathogenesis of affective disorders: an early forerunner.

  Psychological medicine 20110301

• Agomelatine as chronopsychopharmaceutics restoring circadian rhythms and enhancing resilience to stress: a wishfull thinking or an innovative strategy for superior management of depression?

  Psychiatria Danubina 20110301

• Hormone treatment of depression.

  Dialogues in clinical neuroscience 20110301

• Design and synthesis of 4-arylpiperidinyl amide and N-arylpiperdin-3-yl-cyclopropane carboxamide derivatives as novel melatonin receptor ligands.

  Bioorganic & medicinal chemistry letters 20110215

• Does agomelatine block 5-HT2C receptors in humans?

  Psychopharmacology 20110201

• The emerging role of melatonin agonists in the treatment of major depression: focus on agomelatine.

  CNS & neurological disorders drug targets 20110201

• Agomelatine in the treatment of panic disorder.

  Progress in neuro-psychopharmacology & biological psychiatry 20110115

• Melatonin and its agonist ramelteon in Alzheimer's disease: possible therapeutic value.

  International journal of Alzheimer's disease 20110101

• The societal costs of insomnia.

  Neuropsychiatric disease and treatment 20110101

• Switching from serotonin reuptake inhibitors to agomelatine in patients with refractory obsessive-compulsive disorder: a 3 month follow-up case series.

  Annals of general psychiatry 20110101

• Melatonin and the metabolic syndrome: physiopathologic and therapeutical implications.

  Neuroendocrinology 20110101

• Major depressive disorder, anhedonia and agomelatine: an open-label study.

  Journal of biological regulators and homeostatic agents 20110101

• Class effect of pharmacotherapy in bipolar disorder: fact or misbelief?

  Annals of general psychiatry 20110101

• Circadian rhythms, melatonin and depression.

  Current pharmaceutical design 20110101

• The Clinical Global Impression Scale and the influence of patient or staff perspective on outcome.

  BMC psychiatry 20110101

• Melatonin in mitochondrial dysfunction and related disorders.

  International journal of Alzheimer's disease 20110101

• Efficacy of duloxetine and agomelatine does not exceed that of other antidepressants in patients with autistic disorder: preliminary results in 3 patients.

  The primary care companion for CNS disorders 20110101

• Influence of Pre-Training Predator Stress on the Expression of c-fos mRNA in the Hippocampus, Amygdala, and Striatum Following Long-Term Spatial Memory Retrieval.

  Frontiers in behavioral neuroscience 20110101

• Is circadian rhythm disruption important in obsessive-compulsive disorder (OCD)? A case of successful augmentation with agomelatine for the treatment of OCD.

  Clinical neuropharmacology 20110101

• Disruption of circadian rhythms: a crucial factor in the etiology of depression.

  Depression research and treatment 20110101

• [Melatoninergic antidepressant valdoxan].

  Eksperimental'naia i klinicheskaia farmakologiia 20110101

• Fluoxetine during development reverses the effects of prenatal stress on depressive-like behavior and hippocampal neurogenesis in adolescence.

  PloS one 20110101

• Illuminating the deleterious effects of light at night.

  F1000 medicine reports 20110101

• [Possibilities of preventive treatment of migraine with the MT1- and MT2 agonist and 5-HT2с receptor antagonist agomelatin (valdoxan)].

  Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 20110101

• Subchronic peripheral neuregulin-1 increases ventral hippocampal neurogenesis and induces antidepressant-like effects.

  PloS one 20110101

• Disrupted chronobiology of sleep and cytoprotection in obesity: possible therapeutic value of melatonin.

  Neuro endocrinology letters 20110101

• Diazepam discontinuation through agomelatine in schizophrenia with insomnia and depression.

  Journal of clinical psychopharmacology 20101201

• [Lights off? Neurobiological and pharmacological aspects of the melatonergic-serotonergic synergism].

  Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology 20101201

• [Etiopathology and therapy of seasonal affective disorder].

  Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology 20101201

• Effect of agomelatine and its interaction with the daily corticosterone rhythm on progenitor cell proliferation in the dentate gyrus of the adult rat.

  Neuropharmacology 20101101

• Jet lag, circadian rhythm sleep disturbances, and depression: the role of melatonin and its analogs.

  Advances in therapy 20101101

• [QTc prolongation during treatment with agomelatine].

  Psychiatrische Praxis 20101101

• Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomized, double-blind study.

  International clinical psychopharmacology 20101101

• Agomelatine in the treatment of social anxiety disorder.

  Progress in neuro-psychopharmacology & biological psychiatry 20101001

• A systematic, updated review on the antidepressant agomelatine focusing on its melatonergic modulation.

  Current neuropharmacology 20100901

• The novel antidepressant agomelatine normalizes hippocampal neuronal activity and promotes neurogenesis in chronically stressed rats.

  CNS neuroscience & therapeutics 20100801

• Agomelatine, the first melatonergic antidepressant: discovery, characterization and development.

  Nature reviews. Drug discovery 20100801

• Restoring circadian rhythms: a new way to successfully manage depression.

  Journal of psychopharmacology (Oxford, England) 20100801

• The antidepressant agomelatine improves the quality of life of depressed patients: implications for remission.

  Journal of psychopharmacology (Oxford, England) 20100801

• The importance of early symptom relief in antidepressant treatment: focus on agomelatine.

  Journal of psychopharmacology (Oxford, England) 20100801

• Agomelatine for major depressive episodes.

  Drug and therapeutics bulletin 20100801

• Behavioural and neuroplastic effects of the new-generation antidepressant agomelatine compared to fluoxetine in glucocorticoid receptor-impaired mice.

  The international journal of neuropsychopharmacology 20100701

• Agomelatine in the treatment of major depressive disorder: potential for clinical effectiveness.

  CNS drugs 20100601

• Drug treatment of obsessive-compulsive disorder.

  Dialogues in clinical neuroscience 20100601

• Design, synthesis and pharmacological evaluation of novel naphthalenic derivatives as selective MT(1) melatoninergic ligands.

  Bioorganic & medicinal chemistry 20100515

• A randomized double-blind placebo-controlled trial of treatment as usual plus exogenous slow-release melatonin (6 mg) or placebo for sleep disturbance and depressed mood.

  International clinical psychopharmacology 20100501

• Agomelatine in the treatment of major depressive disorder: an 8-week, multicenter, randomized, placebo-controlled trial.

  The Journal of clinical psychiatry 20100501

• Circadian rhythms and depression.

  Australian family physician 20100501

• Impact of the novel antidepressant agomelatine on disturbed sleep-wake cycles in depressed patients.

  Human psychopharmacology 20100401

• Efficacy and safety of agomelatine in the treatment of major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled trial.

  Journal of clinical psychopharmacology 20100401

• [Clinical experiences with agomelatine. The inner ear has to be synchronized again].

  MMW Fortschritte der Medizin 20100311

• Synergistic mechanisms in the modulation of the neurotrophin BDNF in the rat prefrontal cortex following acute agomelatine administration.

  The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry 20100301

• The use of antidepressants in clinical practice: focus on agomelatine.

  Human psychopharmacology 20100301

• Agomelatine in the treatment of mood and anxiety disorders.

  British journal of hospital medicine (London, England : 2005) 20100301

• Melatonin agonists and insomnia.

  Expert review of neurotherapeutics 20100201

• Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline.

  The Journal of clinical psychiatry 20100201

• Better sexual acceptability of agomelatine (25 and 50 mg) compared with paroxetine (20 mg) in healthy male volunteers. An 8-week, placebo-controlled study using the PRSEXDQ-SALSEX scale.

  Journal of psychopharmacology (Oxford, England) 20100101

• Acute stress increases depolarization-evoked glutamate release in the rat prefrontal/frontal cortex: the dampening action of antidepressants.

  PloS one 20100101

• Disruption of biological rhythms as a core problem and therapeutic target in mood disorders: the emerging concept of 'rhythm regulators'.

  Annals of general psychiatry 20100101

• Rationale and design of the randomised clinical trial comparing early medication change (EMC) strategy with treatment as usual (TAU) in patients with major depressive disorder--the EMC trial.

  Trials 20100101

• Depression research: where are we now?

  Molecular brain 20100101

• The emerging modern face of mood disorders: a didactic editorial with a detailed presentation of data and definitions.

  Annals of general psychiatry 20100101

• Blockade of stress-induced increase of glutamate release in the rat prefrontal/frontal cortex by agomelatine involves synergy between melatonergic and 5-HT2C receptor-dependent pathways.

  BMC neuroscience 20100101

• Tinnitus psychopharmacology: A comprehensive review of its pathomechanisms and management.

  Neuropsychiatric disease and treatment 20100101

• Glutamatergic and resting-state functional connectivity correlates of severity in major depression - the role of pregenual anterior cingulate cortex and anterior insula.

  Frontiers in systems neuroscience 20100101

• Oppositional effects of serotonin receptors 5-HT1a, 2, and 2c in the regulation of adult hippocampal neurogenesis.

  Frontiers in molecular neuroscience 20100101

• Getting the balance right: Established and emerging therapies for major depressive disorders.

  Neuropsychiatric disease and treatment 20100101

• Techniques for studying inverse agonist activity of antidepressants at recombinant nonedited 5-HT(₂C-INI) receptor and native neuronal 5-HT(₂C) receptors.

  Methods in enzymology 20100101

• A new strategy for antidepressant prescription.

  Frontiers in neuroscience 20100101

• How antidepressant drugs act: A primer on neuroplasticity as the eventual mediator of antidepressant efficacy.

  Indian journal of psychiatry 20100101

• Psychopharmacology Today: Where are We and Where Do We Go From Here?

  Mens sana monographs 20100101

• Agomelatine: A novel melatonergic antidepressant.

  Journal of pharmacology & pharmacotherapeutics 20100101

• Clinical relevance of disturbances of sleep and vigilance in major depressive disorder: a review.

  Primary care companion to the Journal of clinical psychiatry 20100101

• Delayed onset of the diurnal melatonin rise in patients with Huntington's disease.

  Journal of neurology 20091201

• [Further evidence of the efficacy of the antidepressant Valdoxan (agomelatine) compared with conventional antidepressive drugs (from the ECNP held in Istanbul, 15 September 2009)].

  L'Encephale 20091201

• Agomelatine: new drug. Adverse effects and no proven efficacy.

  Prescrire international 20091201

• Mechanisms contributing to the phase-dependent regulation of neurogenesis by the novel antidepressant, agomelatine, in the adult rat hippocampus.

  Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20091001

• Agomelatine, a melatonin agonist with antidepressant properties.

  Expert opinion on investigational drugs 20091001

• Emerging drugs for major depressive disorder.

  Expert opinion on emerging drugs 20090901

• Sexual side-effects of contemporary antidepressants: review.

  The Australian and New Zealand journal of psychiatry 20090901

• Bidirectional communication between sleep and circadian rhythms and its implications for depression: lessons from agomelatine.

  Progress in neurobiology 20090801

• Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial.

  The Journal of clinical psychiatry 20090801

• [Agomelatine].

  Medizinische Monatsschrift fur Pharmazeuten 20090801

• Agomelatine: a novel pharmacological approach to treating depression.

  Drugs of today (Barcelona, Spain : 1998) 20090801

• Influence of the novel antidepressant and melatonin agonist/serotonin2C receptor antagonist, agomelatine, on the rat sleep-wake cycle architecture.

  Psychopharmacology 20090701

• Overexpression of 5-HT2C receptors in forebrain leads to elevated anxiety and hypoactivity.

  The European journal of neuroscience 20090701

• Current investigational drugs for major depression.

  Expert opinion on investigational drugs 20090601

• Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis.

  Journal of clinical psychopharmacology 20090601

• [Clinically relevant drug interactions with new generation antidepressants and antipsychotics].

  Therapeutische Umschau. Revue therapeutique 20090601

• The DSM-IV-based Generalized Anxiety Disorder Severity Scale: preliminary validation using data from a trial of agomelatine versus placebo.

  The Journal of nervous and mental disease 20090601

• [Depression as chronobiological illness].

  Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology 20090601

• Agomelatine improves symptoms of generalised anxiety disorder.

  Evidence-based mental health 20090501

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20090501

• The antidepressant agomelatine blocks the adverse effects of stress on memory and enables spatial learning to rapidly increase neural cell adhesion molecule (NCAM) expression in the hippocampus of rats.

  The international journal of neuropsychopharmacology 20090401

• Pathophysiology of depression: role of sleep and the melatonergic system.

  Psychiatry research 20090227

• The effect of melatonergic and non-melatonergic antidepressants on sleep: weighing the alternatives.

  The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry 20090101

• Chronic mild stress (CMS) in mice: of anhedonia, 'anomalous anxiolysis' and activity.

  PloS one 20090101

• Pharmacology of ramelteon, a selective MT1/MT2 receptor agonist: a novel therapeutic drug for sleep disorders.

  CNS neuroscience & therapeutics 20090101

• Beyond the monoaminergic hypothesis: agomelatine, a new antidepressant with an innovative mechanism of action.

  The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry 20090101

• Melatonin and melatonergic drugs on sleep: possible mechanisms of action.

  The International journal of neuroscience 20090101

• Insomnia in patients with depression: some pathophysiological and treatment considerations.

  CNS drugs 20090101

• Melatonin receptor agonist agomelatine: a new drug for treating unipolar depression.

  Current pharmaceutical design 20090101

• New approaches in the management of insomnia: weighing the advantages of prolonged-release melatonin and synthetic melatoninergic agonists.

  Neuropsychiatric disease and treatment 20090101

• Agomelatine: innovation for the benefit of depressed patients.

  CNS drugs 20090101

• Neurobiology of circadian systems.

  CNS drugs 20090101

• Disruption of the circadian timing systems: molecular mechanisms in mood disorders.

  CNS drugs 20090101

• Agomelatine: innovative pharmacological approach in depression.

  CNS drugs 20090101

• Clinical studies on the efficacy of agomelatine on depressive symptoms.

  CNS drugs 20090101

• Agomelatine: efficacy at each phase of antidepressant treatment.

  CNS drugs 20090101

• Sleep disturbances: core symptoms of major depressive disorder rather than associated or comorbid disorders.

  The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry 20090101

• Pharmacological and combined interventions for the acute depressive episode: focus on efficacy and tolerability.

  Therapeutics and clinical risk management 20090101

• Critical appraisal and update on the clinical utility of agomelatine, a melatonergic agonist, for the treatment of major depressive disease in adults.

  Neuropsychiatric disease and treatment 20090101

• [Sleep disturbances--cause or result of depression].

  Psychiatria polska 20090101

• Agomelatine: The evidence for its place in the treatment of depression.

  Core evidence 20090101

• Chronic fluoxetine treatment increases daytime melatonin synthesis in the rodent.

  Clinical pharmacology : advances and applications 20090101

• Agomelatine treatment of major depressive disorder.

  The Annals of pharmacotherapy 20081201

• Cellular and molecular mechanisms in the long-term action of antidepressants.

  Dialogues in clinical neuroscience 20081201

• Extreme creatine phosphokinase elevation in a 20-year-old man participating in a clinical trial of major depressive disorder.

  The Journal of clinical psychiatry 20081101

• Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study.

  Journal of clinical psychopharmacology 20081001

• Melatonin and its agonists: an update.

  The British journal of psychiatry : the journal of mental science 20081001

• Synthesis of 3-phenylnaphthalenic derivatives as new selective MT(2) melatoninergic ligands.

  Bioorganic & medicinal chemistry 20080915

• Agomelatine: a novel mechanism of antidepressant action involving the melatonergic and the serotonergic system.

  European psychiatry : the journal of the Association of European Psychiatrists 20080901

• Major depression is sometimes described as the common cold of psychiatry.

  Journal of psychopharmacology (Oxford, England) 20080901

• Agomelatine, an innovative pharmacological response to unmet needs.

  Journal of psychopharmacology (Oxford, England) 20080901

• Innovation translates into antidepressant effectiveness.

  Journal of psychopharmacology (Oxford, England) 20080901

• Addressing circadian rhythm disturbances in depressed patients.

  Journal of psychopharmacology (Oxford, England) 20080901

• Treating each and every depressed patient.

  Journal of psychopharmacology (Oxford, England) 20080901

• Agomelatine adjunctive therapy for acute bipolar depression: preliminary open data.

  Bipolar disorders 20080901

• Core symptoms of major depressive disorder: relevance to diagnosis and treatment.

  Dialogues in clinical neuroscience 20080901

• Effects of different antidepressant treatments on the core of depression.

  Dialogues in clinical neuroscience 20080901

• Serum S100B Levels and Major Depressive Disorder: Its Characteristics and Role in Antidepressant Response.

  Psychiatry investigation 20080901

• Agomelatine, a melatonin receptor agonist with 5-HT(2C) receptor antagonist properties, protects the developing murine white matter against excitotoxicity.

  European journal of pharmacology 20080624

• A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR.

  Journal of clinical psychopharmacology 20080601

• Promising avenues of therapeutics for bipolar illness.

  Dialogues in clinical neuroscience 20080601

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20080401

• Jet lag: therapeutic use of melatonin and possible application of melatonin analogs.

  Travel medicine and infectious disease 20080101

• Melatonergic drugs in clinical practice.

  Arzneimittel-Forschung 20080101

• Agomelatine: AGO 178, AGO178, S 20098.

  Drugs in R&D 20080101

• Melatonin receptor agonists: SAR and applications to the treatment of sleep-wake disorders.

  Current topics in medicinal chemistry 20080101

• Non-REM sleep instability in patients with major depressive disorder: subjective improvement and improvement of non-REM sleep instability with treatment (Agomelatine).

  Sleep medicine 20071201

• A review of the efficacy and tolerability of agomelatine in the treatment of major depression.

  Expert opinion on investigational drugs 20071201

• Agomelatine: a novel atypical antidepressant.

  Journal of psychosocial nursing and mental health services 20071201

• Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine.

  The Journal of clinical psychiatry 20071101

• Major depressive disorder, sleep EEG and agomelatine: an open-label study.

  The international journal of neuropsychopharmacology 20071001

• Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder.

  The international journal of neuropsychopharmacology 20071001

• Evidence of agomelatine's antidepressant efficacy: the key points.

  International clinical psychopharmacology 20071001

• High-quality remission: potential benefits of the melatonergic approach for patients with major depressive disorder.

  International clinical psychopharmacology 20071001

• The interaction between the internal clock and antidepressant efficacy.

  International clinical psychopharmacology 20071001

• New antidepressants or more of the same?

  Neuropsychiatric disease and treatment 20071001

• [Pharmacotherapy of depression: recent developments].

  Revue medicale suisse 20070919

• Severe depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatine.

  International clinical psychopharmacology 20070901

• Agomelatine adjunctive therapy for acute bipolar depression: preliminary open data.

  Bipolar disorders 20070901

• The phase shift hypothesis for the circadian component of winter depression.

  Dialogues in clinical neuroscience 20070901

• Agomelatine and its therapeutic potential in the depressed patient.

  Neuropsychiatric disease and treatment 20070801

• First evidence of melatonin receptors distribution in the suprachiasmatic nucleus of tree shrew brain.

  Neuro endocrinology letters 20070601

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20070601

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20070501

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20070401

• Agomelatine in the treatment of seasonal affective disorder.

  Psychopharmacology 20070301

• Emerging treatments for major depression.

  Expert review of neurotherapeutics 20070201

• [Melatonin, melatonin receptor agonists and tryptophan as sleep aids].

  Pharmazie in unserer Zeit 20070101

• Hippocampal neurogenesis, depressive disorders, and antidepressant therapy.

  Neural plasticity 20070101

• Role of the melatonin system in the control of sleep: therapeutic implications.

  CNS drugs 20070101

• [New hypnotics: perspectives from sleep physiology].

  Vertex (Buenos Aires, Argentina) 20070101

• Antidepressant-like effects of agomelatine (S 20098) in the learned helplessness model.

  Behavioural pharmacology 20061201

• Could agomelatine be the ideal antidepressant?

  Expert review of neurotherapeutics 20061101

• [Agomelatine: the first 'melatoninergic' antidepressant].

  Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology 20061001

• New directions for drug discovery.

  Dialogues in clinical neuroscience 20060901

• Effects of melatonin and agomelatine in anxiety-related procedures in rats: interaction with diazepam.

  European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 20060801

• Melatonin: Nature's most versatile biological signal?

  The FEBS journal 20060701

• Agomelatine targets a range of major depressive disorder symptoms.

  Current opinion in investigational drugs (London, England : 2000) 20060701

• Agomelatine, a new antidepressant, induces regional changes in hippocampal neurogenesis.

  Biological psychiatry 20060601

• Future prospects in depression research.

  Dialogues in clinical neuroscience 20060601

• Treatments in depression.

  Dialogues in clinical neuroscience 20060601

• Depression and sleep: pathophysiology and treatment.

  Dialogues in clinical neuroscience 20060601

• Homology modelling of the serotoninergic 5-HT2c receptor.

  Journal of enzyme inhibition and medicinal chemistry 20060601

• Prospects for the treatment of depression.

  The Australian and New Zealand journal of psychiatry 20060501

• Placebo-controlled trial of agomelatine in the treatment of major depressive disorder.

  European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 20060201

• Anxiolytic-like activity of agomelatine and melatonin in three animal models of anxiety.

  Behavioural pharmacology 20060201

• Why do we need new and better antidepressants?

  International clinical psychopharmacology 20060201

• Biological rhythm disturbances in mood disorders.

  International clinical psychopharmacology 20060201

• Pharmacology of a new antidepressant: benefit of the implication of the melatonergic system.

  International clinical psychopharmacology 20060201

• Clinical efficacy of agomelatine in depression: the evidence.

  International clinical psychopharmacology 20060201

• Sleep disturbances and depression: a challenge for antidepressants.

  International clinical psychopharmacology 20060201

• Efficacy and tolerance profile of agomelatine and practical use in depressed patients.

  International clinical psychopharmacology 20060201

• Therapeutic potential of melatonin ligands.

  Chronobiology international 20060101

• Agomelatine: a preliminary review of a new antidepressant.

  CNS drugs 20060101

• Antidepressant-like effects of agomelatine, melatonin and the NK1 receptor antagonist GR205171 in impulsive-related behaviour in rats.

  Psychopharmacology 20051001

• Anxiolytic-like action of the antidepressant agomelatine (S 20098) after a social defeat requires the integrity of the SCN.

  European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 20051001

• [Development of a new antidepressant : agomelatine].

  Medecine sciences : M/S 20051001

• Phase-shifts of 24-h rhythms of hormonal release and body temperature following early evening administration of the melatonin agonist agomelatine in healthy older men.

  Clinical endocrinology 20050901

• Antidepressant action of agomelatine (S 20098) in a transgenic mouse model.

  Progress in neuro-psychopharmacology & biological psychiatry 20050701

• Recent advances in melatonin receptor ligands.

  Archiv der Pharmazie 20050601

• Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade.

  Psychopharmacology 20050201

• Newer treatment studies for bipolar depression.

  Bipolar disorders 20050101

• [Depression and neuroplasticity: implication of serotoninergic systems].

  Therapie 20050101

• RNA expression of human telomerase subunits TR and TERT is differentially affected by melatonin receptor agonists in the MCF-7 tumor cell line.

  Cancer letters 20041208

• Melatonin, sleep, and circadian rhythms: rationale for development of specific melatonin agonists.

  Sleep medicine 20041101

• Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study.

  International clinical psychopharmacology 20040901

• Differential effects of the novel antidepressant agomelatine (S 20098) versus fluoxetine on 5-HT1A receptors in the rat brain.

  Neuropharmacology 20040901

• Antidepressant-like activity of S 20098 (agomelatine) in the forced swimming test in rodents: involvement of melatonin and serotonin receptors.

  Journal of psychiatry & neuroscience : JPN 20040301

• Chronobiology and mood disorders.

  Dialogues in clinical neuroscience 20031201

• Treatment of seasonal affective disorders.

  Dialogues in clinical neuroscience 20031201

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20031101

• Agomelatine(S 20098) antagonizes the penile erections induced by the stimulation of 5-HT2C receptors in Wistar rats.

  Psychopharmacology 20031001

• The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways.

  The Journal of pharmacology and experimental therapeutics 20030901

• New selective ligands of human cloned melatonin MT1 and MT2 receptors.

  Naunyn-Schmiedeberg's archives of pharmacology 20030601

• Melatonin counteracts the inhibitory effect of PGE2 on IL-2 production in human lymphocytes via its mt1 membrane receptor.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20030401

• Effect of agomelatine in the chronic mild stress model of depression in the rat.

  Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20030401

• Design and synthesis of naphthalenic dimers as selective MT1 melatoninergic ligands.

  Journal of medicinal chemistry 20030327

• Gateways to clinical trials. March 2003.

  Methods and findings in experimental and clinical pharmacology 20030301

• [Pilot study comparing in blind the therapeutic effect of two doses of agomelatine, melatonin- agonist and selective 5HT2c receptors antagonist, in the treatment of major depressive disorders].

  L'Encephale 20030101

• Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study.

  International clinical psychopharmacology 20020901

• Gateways to Clinical Trials.

  Methods and findings in experimental and clinical pharmacology 20020901

• [Pilot study comparing in blind the therapeutic effect of two doses of agomelatine, melatoninergic agonist and selective 5HT2C receptors antagonist, in the treatment of major depressive disorders].

  L'Encephale 20020101

• S20098 affects the free-running rhythms of body temperature and activity and decreases light-induced phase delays of circadian rhythms of the rat.

  Chronobiology international 20010901

• Melatonin or a melatonin agonist corrects age-related changes in circadian response to environmental stimulus.

  American journal of physiology. Regulatory, integrative and comparative physiology 20010501

• Serine residues 110 and 114 are required for agonist binding but not antagonist binding to the melatonin MT(1) receptor.

  Biochemical and biophysical research communications 20010420

• Evidence of melatonin involvement in pindolol-induced suppression of REM sleep.

  Journal of neural transmission (Vienna, Austria : 1996) 20010101

• Synthesis of phenalene and acenaphthene derivatives as new conformationally restricted ligands for melatonin receptors.

  Journal of medicinal chemistry 20001102

• GR196429: a nonindolic agonist at high-affinity melatonin receptors.

  The Journal of pharmacology and experimental therapeutics 19980601